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ABSTRACT
Background: Previous studies have presented contra-
dictory data concerning obstructive sleep apnoea
syndrome (OSAS), lipid oxidation and nitric oxide (NO)
bioavailability. This study was undertaken to (1) compare
the concentration of 8-isoprostane and total nitrate and
nitrite (NOx) in plasma of middle-aged men with OSAS
and no other known co-morbidity and healthy controls of
the same age, gender and body mass index; and (2) test
the hypothesis that nasal continuous positive airway
pressure (CPAP) therapy attenuates oxidative stress and
nitrate deficiency.
Methods: A prospective, randomised, placebo controlled,
double-blind, crossover study was performed in 31
consecutive middle-aged men with newly diagnosed
OSAS and 15 healthy control subjects. Patients with
OSAS were randomised to receive sham CPAP or
effective CPAP for 12 weeks. Blood pressure, urinary
catecholamine levels and plasma 8-isoprostane and NOx
concentrations were obtained before and after both
treatment modalities.
Results: Patients with OSAS had significantly higher 8-
isoprostane levels (median (IQR) 42.5 (29.2–78.2) vs 20.0
(12.5–52.5) pg/ml, p = 0.041, Mann-Whitney test) and
lower NOx levels (264 (165–650) vs 590 (251–
1465) mmol/l, p = 0.022) than healthy subjects. Body
mass index, blood pressure and urinary catecholamines
were unchanged by CPAP therapy, but 8-isoprostane
concentrations decreased (38.5 (24.2–58.7) pg/ml at
baseline vs 22.5 (16.2–35.3) pg/ml on CPAP, p = 0.0001)
and NOx levels increased (280 (177–707) vs 1373
(981–1517) mmol/l, p = 0.0001) after CPAP.
Conclusions: OSAS is associated with an increase in
oxidative stress and a decrease in NOx that is normalised
by CPAP therapy.
Cardiovascular morbidity and mortality is
increased in patients with obstructive sleep apnoea
syndrome (OSAS).1–6 Oxidative and nitrosative
stress are believed to contribute to this associa-
tion7–9 because markers of lipid peroxidation appear
to be increased in the plasma, exhaled breath
condensate and urine of these patients.10–14
However, not all studies have been able to replicate
these observations.15–17 Potential confounding fac-
tors explaining this discrepancy may include age
differences between patients and controls, the
smoking history of the patients and/or the
presence of co-morbidities such as obesity, chronic
obstructive pulmonary disease (COPD) or cardio-
vascular disease, all of which are common in OSAS
and can be associated with oxidative stress by
themselves.2 4 5 The effect of continuous positive
airway pressure (CPAP) therapy on these biological
abnormalities is also controversial. Whereas some
uncontrolled studies have shown that CPAP
therapy decreases oxidative stress in these
patients,10 12 13 18–21 other groups have failed to
demonstrate any significant change after CPAP.16 17
To address these limitations we designed a
prospective, randomised, double-blind, placebo con-
trolled, crossover study that sought to (1) compare
the concentration of 8-isoprostane and total nitrate
and nitrite (NOx) in plasma of middle-aged men
with OSAS in whom lung and cardiovascular
diseases were carefully excluded and in healthy
controls of the same age, gender and body mass
index (BMI); and (2) test the hypothesis that CPAP
therapy improves oxidative stress and nitrate
deficiency in these patients.
METHODS
Subjects
Thirty-one consecutive newly diagnosed men with
OSAS and 15 healthy male volunteers were included
in the study. All patients with OSAS fulfilled all the
following inclusion criteria: (1) apnoea-hypopnea
index (AHI)>10/h; (2) excessive daytime sleepiness
defined by an Epworth scale score of >11 points;
and (3) no treatment for OSAS. Inclusion criteria for
healthy control subjects were AHI ,5/h and
Epworth sleepiness scale ,10. Exclusion criteria
for both study groups were: (1) unwillingness or
inability to participate in the study; (2) obstructive
or restrictive lung disease as identified by pulmon-
ary function testing; (3) use of cardioactive drugs;
(4) cardiac rhythm disturbances, including sinus
bradycardia and sinus tachycardia; (5) known
arterial hypertension or 24 h ambulatory blood
pressure monitoring (ABPM) showing blood pres-
sure values >135/85 mm Hg; (6) left ventricular
ejection fraction ,50%, ischaemic or valve heart
disease, hypertrophic, restrictive or infiltrative
cardiomyopathy, pericardial disease or stroke by
history, physical examination, ECG, chest radio-
graphy, conventional exercise stress testing and
echocardiography; (7) diabetes mellitus by history
or two random blood glucose levels >126 mg/dl;
(8) morbid obesity (BMI .40 kg/m2); and/or
(9) daytime hypoxaemia (PaO2 ,70 mm Hg) or
hypercapnia (PaCO2 .45 mm Hg). Other exclusion
criteria during the study period were: (1) need to
change medication; (2) hospital admission for 10 or
more days; and (3) average nightly CPAP usage less
than 3.5 h. Control subjects were recruited from a
list of healthy subjects from our sanitary area who
had had a routine health test in the previous
3 months. We randomly selected a control subject
similar in gender, age (¡2 years), weight (¡2 kg)
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and height (¡5 cm) with regard to the two preceding patients
included in the study.
Study design
A single-centre, prospective, randomised, double-blind, placebo
controlled, crossover clinical study was performed in which
patients received CPAP and sham therapy22 for two 12-week
periods. In healthy controls measurements were obtained once.
At recruitment, ABPM, echocardiography, catecholamine con-
centration in urine and a sleep study were undertaken in all
participants. After fasting overnight, a venous blood sample
(anticoagulated with dipotassium EDTA for determination of 8-
isoprostane and total nitrate and nitrite (NOx) concentrations)
was collected from all participants between 08.00 and 10.00 h.
Within 30 min of blood collection, plasma was obtained by
centrifugation at 3000 rpm for 15 min. All plasma samples were
stored at 260uC until analysis.
Patients with OSAS underwent a full-night CPAP titration
study at home using an automated pressure setting device (Auto
Set; ResMed, Sydney, Australia).23 Patients were given detailed
instructions on the appropriate use of the CPAP equipment and
were randomised to receive either effective or sham CPAP
therapy for 12 weeks. The sham CPAP device was a modified
conventional CPAP device in which the exhalation port
diameter had been enlarged to nearly cancel nasal pressure
and an orifice resistor was connected between the tubing and
the CPAP unit that loads the blower with the same airflow
resistance as in effective CPAP.22 No information about the type
of therapy they were receiving was given. Compliance with
therapy was obtained from a built-in run time counter. After
12 weeks the CPAP device was switched to the alternate mode
of therapy and ABPM and plasma and urine sampling were
repeated (fig 1).
Measurements
A validated portable recording device (Sibel Home-300; Sibel SA,
Barcelona, Spain)24 that records oronasal airflow using a
thermistor and nasal cannula prongs, chest wall impedance,
oxygen saturation, snoring and body position was used to
perform a sleep study in patients and healthy controls.
Respiratory events were classified as either obstructive or
central on the basis of the presence or absence of respiratory
effort. Respiratory events were scored as apnoeas when there
was a cessation of oronasal airflow lasting >10 s. Hypopnoea
was defined as a decrease of 50% in oronasal airflow lasting
.10 s associated with a fall in arterial oxygen saturation (SaO2)
.4% of the preceding baseline level. Mean night time SaO2,
minimum SaO2 (lowest values recorded during sleep), desatura-
tion index and percentage of time with SaO2 ,90% on
nocturnal oximetry were computed as indices of nocturnal
oxygen saturation.
Twenty-four hour ABPM data were obtained using an
oscillometric method (Spacelabs device, Model 90207;
Redmond, Washington, USA).25 Blood pressure was measured
every 30 min during the day (08.00 to 23.00 h) and every
60 min during the night (23.00 to 08.00 h) on a workday. An
appropriate cuff was placed on the non-dominant arm. Patients
were instructed to carry out their ordinary daily activities, to go
to bed no later than 23.00 h and not to move their arm during
recordings.
Echocardiography was performed in the supine and left lateral
positions after a minimum rest period of 30 min using a high
quality echocardiograph with 2.0–4.0 MHz probes (Hewlett
Packard Sonos 5500; Andover, Massachusetts, USA).
Echocardiographic images were obtained in the parasternal long
and short axes, apical two-chamber and four-chamber and
subcostal views using two-dimensional, M-mode and Doppler
echocardiographic techniques. The parameters were measured
from at least three cardiac cycles. All echocardiograms were
performed by the same experienced echocardiographer who was
unaware of the subject group or the treatment assignment at
each visit. Systolic function was assessed by left ventricular
shortening fraction (LVSF) and left ventricular ejection fraction
(LVEF);26 LVSF >28% and LVEF >50% were considered normal.
Forced spirometry was performed as previously described
using a MasterScope system (Jaeger, Wu¨rtzburg, Germany).25
At each visit, subjects were requested to collect separate urine
samples from 08.00 h until going to bed (day) and all urine
during the night and the first sample after getting up in the
morning (night). The urinary excretion of norepinephrine and
epinephrine was determined as previously described.27
A specific enzyme immunoassay kit (Cayman Chemical, Ann
Arbor, Michigan, USA) was used to measure 8-isoprostane
Figure 1 Flow chart of study subjects.
CPAP, continuous positive airway
pressure; OSAS, obstructive sleep apnoea
syndrome.
Sleep-disordered breathing
582 Thorax 2009;64:581–586. doi:10.1136/thx.2008.100537
 on 6 July 2009 thorax.bmj.comDownloaded from 
concentrations in plasma. The intra-assay and inter-assay
variability were 5% and 7%, respectively, and the detection
limit of the assay was 5 pg/ml.
Total nitrate and nitrite (NOx) were measured in plasma by
capillary electrophoresis using a Beckman capillary electrophor-
esis system (P/ACE MDQ). Absorbance was read at 200 nm and
nitrate concentration was determined using a NaNO3 standard.
The lower detection limit was 10 mmol/l and the intra-assay
and inter-assay variability were 5% and 8%, respectively.
Statistical analysis
Values are expressed as mean (SD) or median (interquartile
range, IQR) depending on their distribution. All statistical tests
were two-sided. Comparisons between groups were performed
using the Student t test or the Mann-Whitney U test.
Categorical variables were compared using the x2 test.
Bivariate relationships between variables were determined by
Pearson’s or Spearman’s correlation. To investigate the effect of
CPAP therapy over time in patients with OSAS, repeated
measures ANOVA was used with treatment (effective CPAP vs
sham CPAP) as a within-subject factor and order of therapy as a
between-subject factor. Whenever ANOVA results indicated the
existence of significant differences between treatment condi-
tions, post hoc multiple comparisons were performed with the
Bonferroni test. A p value of ,0.05 was considered statistically
significant. All analyses were performed using the SPSS Version
11.0 software (SPSS, Chicago, Illinois, USA).
RESULTS
Characteristics of subjects
Seven subjects refused to take part in the study and three were
deemed ineligible for inclusion after initial assessments (one had
diabetes mellitus and two because they had unknown mitral
stenosis), so 31 patients with OSAS were randomised for
inclusion in the study (fig 1).
Table 1 shows the main demographic and functional
characteristics of all participants at baseline. Demographic data,
smoking habits, spirometric results and ABPM results did not
differ between patients with OSAS and healthy controls. As
expected, sleep parameters were abnormal (and consistent with
the diagnosis of OSAS) in patients but were normal in healthy
subjects. Patients with OSAS had higher nocturnal levels of
norepinephrine and epinephrine than control subjects but LVSF
and LVEF were similar in both groups.
Plasma concentrations of 8-isoprostane and total nitrate and
nitrite (NOx)
At recruitment, before treatment with CPAP, patients with
OSAS had higher median (IQR) plasma levels of 8-isoprostane
(42.5 (29.2–78.2) vs 20.0 (12.5–52.5) pg/ml, p = 0.041) and lower
plasma levels of NOx (264 (165–650) vs 590 (251–1465) mmol/l,
p = 0.022) than healthy subjects. There were no correlations
between plasma levels of 8-isoprostane or NOx and sleep
parameters.
Effects of CPAP
Six patients failed to complete the trial, leaving 25 patients for
the final analysis. Two were excluded because, on average, they
used CPAP at night for ,3.5 h, while the remaining four
patients were lost to follow-up (fig 1). The baseline anthropo-
metric characteristics, smoking habit, lung function data, sleep
study indices, sympathetic tone, ABPM or left ventricular
systolic function of these six patients were not significantly
different from those who completed the trial. The mean (SD)
CPAP pressure value was 10 (2) cm H2O and average nightly
use of CPAP and sham CPAP was 6.2 (1.1) h and 6.3 (1.6) h,
respectively.
BMI, ABPM and urinary catecholamines were not modified by
CPAP (table 2). However, effective CPAP (but not sham CPAP)
significantly decreased the plasma concentration of 8-isoprostane
(from 38.5 (24.2–58.7) pg/ml to 22.5 (16.2–35.3) pg/ml,
p = 0.0001) and increased the plasma concentration of NOx
(from 280 (177–707) mmol/l to 1373 (981–1517) mmol/l,
p = 0.0001, fig 2). The decrease in 8-isoprostane concentration
was similar in the OSAS subgroup treated with optimal CPAP
and sham CPAP to that in the OSAS group treated with
sham CPAP and optimal CPAP (18.3 (1.1–25.0) pg/ml vs
21.6 (4.0–25.6) pg/ml, p = 0.276). The increase in NOx concen-
tration was also not affected by the treatment order (827
(563–974) mmol/l vs 961 (630–1309) mmol/l, p = 0.921). Values
after CPAP therapy were not significantly different from those
found in healthy subjects.
DISCUSSION
Our study provides two main findings of interest. First, the
plasma concentration of 8-isoprostane is higher and that of
NOx is lower in patients with OSAS carefully selected to
exclude pulmonary and cardiovascular disease than in healthy
Table 1 Baseline clinical and functional characteristics of study
subjects
Control subjects
(n = 15)
OSAS patients
(n = 31)
Age (years) 48 (10) 52 (13)
BMI (kg/m2) 28.7 (4.7) 30.5 (4.0)
Smokers (%) 27 35
Pack/years 20 (7) 20 (12)
AHI (/h) 3.7 (3.3) 43.8 (27.0)*
Mean SaO2 (%) 94 (2) 91 (6){
Minimum SaO2 (%) 85 (5) 72 (15){
CT90%SaO2 0.0 (0–0.05) 6.3 (2.0–29.8)*
Desaturation index (/h) 4.0 (3.0–7.5) 41.2 (18.9–63.3)*
FVC (% predicted) 99 (16) 105 (17)
FEV1 (% predicted) 108 (16) 111 (15)
FEV1/FVC (%) 88.2 (3.6) 85.8 (7.2)
Daytime ambulatory BP
(mm Hg)
Systolic 122 (9) 126 (10)
Diastolic 78 (5) 79 (6)
Night time ambulatory BP
(mm Hg)
Systolic 110 (10) 117 (11)
Diastolic 67 (6) 70 (7)
Norepinephrine (mg/g)
Diurnal 22.5 (19.6–30.1) 33.2 (26.6–46.5)
Nocturnal 11.3 (7.2–16.7) 22.2 (13.9–29.4){
Epinephrine (mg/g)
Diurnal 6.9 (3.4–10.3) 7.2 (4.0–11.8)
Nocturnal 3.4 (2.2–4.9) 6.3 (3.8–9.9){
LVSF (%) 40.1 (4.8) 37.6 (3.1)
LVEF (%) 70.1 (5.9) 67.1 (3.7)
*p,0.001, {p,0.01, {p,0.05 (Student t test or Mann-Whitney U test).
Values are mean (SD) or median (interquartile range) depending on the distribution.
AHI, apnoea-hypopnoea index; BMI, body mass index; BP, blood pressure;
CT90%, percentage of total time study with SaO2 ,90%; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; LVSF,
left ventricular shortening fraction; OSAS, obstructive sleep apnoea syndrome; SaO2,
oxygen saturation.
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subjects matched for gender, age and BMI. Second, these
abnormalities are normalised after 12 weeks of CPAP therapy.
Despite the fact that some previous studies have provided
similar results, to the best of our knowledge ours is the first
prospective randomised placebo controlled crossover study to
evaluate oxidative stress and NO bioavailability in patients with
OSAS and the effects of CPAP therapy on these parameters. Our
results therefore provide a definite answer to some still
unanswered questions in this field.
Oxidative stress
Many previous studies have identified an association between
OSAS and cardiovascular disease.1 3 Oxidative stress is often
proposed as a likely pathogenic mechanism.28 29 However,
earlier studies of lipid peroxidation in OSAS provided conflict-
ing results. Some of them could not find differences in the
susceptibility to lipid peroxidation in these patients.15–17 This is
best exemplified by the study of Svatikova et al16 who reported
that the concentration of thiobarbituric acid-reactive sub-
stances, oxidised LDL autoantibodies and free isoprostane
levels in 41 patients with severe OSAS without cardiovascular
co-morbidity were similar to those of 35 healthy controls
matched for BMI and age. However, they did not measure lung
or left ventricular function, and controls were recruited from
those who attended their sleep unit and had an AHI ,5/h even
though they had a relatively high sleep fragmentation index
(22 (4)/h). Moreover, they employed a split-night protocol
which is, in our opinion, unsuitable to investigate biomarker
changes in these patients.16 On the other hand, several other
studies reported abnormal lipid peroxidation in OSAS.10–14 For
instance, Carpagnano et al11 found higher levels of 8-isprostane
in plasma and exhaled breath condensate in patients with
OSAS than in controls, and Minoguchi et al demonstrated that
the urinary levels of 8-isprostane in OSAS were related to the
AHI.14 Isoprostanes are a complex family of compounds
produced from arachidonic acid via a free radical catalysed
mechanism.30 They are often used as clinical markers of lipid
peroxidation in human diseases because of their stability and
specificity.29 We found that patients with OSAS in whom
pulmonary and cardiac co-morbidities were carefully excluded
had higher 8-isoprostane plasma levels than healthy controls,
and that CPAP therapy (but not treatment with sham CPAP)
normalised these values. The results of studies investigating
Table 2 Effects of continuous positive airway pressure (CPAP) on blood pressure (BP) and urinary
catecholamines, oxidative stress and nitrate and nitrite concentrations in patients with obstructive sleep
apnoea syndrome
Baseline Sham CPAP Therapeutic CPAP
Weight (kg) 88.8 (14.5) 88.6 (15.2) 88.4 (15.8)
Daytime ambulatory BP (mm Hg)
Systolic 126 (10) 126 (12) 127 (9)
Diastolic 79 (6) 77 (6) 78 (5)
Nighttime ambulatory BP (mm Hg)
Systolic 118 (12) 117 (12) 117 (17)
Diastolic 70 (8) 70 (6) 69 (9)
Norepinephrine (mg/g)
Diurnal 32.9 (26.6–47.5) 32.2 (25.3–41.8) 32.8 (21.1–37.5)
Nocturnal 20.6 (15.4–32.7) 16.4 (13.9–27.5) 19.8 (14.8–29.4)
Epinephrine (mg/g)
Diurnal 7.0 (3.9–11.5) 7.2 (4.7–11.2) 7.3 (4.9–10.5)
Nocturnal 6.2 (3.9–11.3) 4.6 (3.7–7.5) 5.4 (3.7–10.9)
8-isoprostane (pg/ml) 38.5 (24.2–58.7) 42.1 (34.7–50.1) 22.5 (16.2–35.3){{
NOx (mmol/l) 280 (177–707) 494 (292–940) 1373 (981–1517){{
Values are mean (SD) or median (interquartile range) depending on the distribution.
{p,0.001 vs baseline; {p,0.001 vs sham CPAP.
NOx, total nitrate and nitrite concentration in plasma.
Figure 2 Individual plasma concentrations of (A) 8-isoprostane and
(B) nitrate and nitrite (NOx) at baseline, after sham continuous positive
airway pressure (CPAP) and optimal CPAP in patients with obstructive
sleep apnoea syndrome.
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the effects of CPAP therapy on oxidative stress in OSAS have
also yielded conflicting results. On the one hand, several
uncontrolled studies showed that short-term,11 medium-
term12 14 21 and long-term10 13 20 CPAP reduces oxidative stress
in patients with OSAS. In addition, Barcelo´ et al18 found that
treatment with CPAP for 1 year increased the plasma
antioxidant status. In contrast, other groups failed to
demonstrate that CPAP had any effect on oxidative stress
and antioxidant capacity.16 17 The differences between the
studies may be due to the effects of several potential
confounders and the fact that none of them was controlled
by sham CPAP. In our study we sought to avoid these
limitations by selecting participants (both patients with OSAS
and controls) very carefully so that all of them were free of any
other co-morbid disease and none was receiving medication
either before or during the study period. Furthermore, we
recruited into the study healthy subjects in whom subclinical
pulmonary or cardiac disease was carefully excluded and, most
importantly, we designed a placebo controlled crossover study
which is the most powerful design for testing the efficacy of
any therapeutic intervention. Under these circumstances, our
results clearly show that effective CPAP therapy improves
oxidative stress in patients with OSAS (table 2, fig 2). Taking
into account all the above-mentioned arguments, we postulate
that our results clearly show that OSAS produces oxidative
stress and that this is treatable with CPAP.
Nitrate and nitrite (NOx) deficiency
Impaired nitric oxide (NO) release from endothelial cells is also
regarded as an initiator and promoter of cardiovascular disease in
patients with OSAS. Nitrate and nitrite (NOx) are stable
derivatives of NO and their levels reflect overall NO production.31
Previous studies have shown that NO production is lower in
patients with OSAS than in controls.7–9 32 In keeping with these
results, we also found that NOx levels were lower in OSAS than
in an age- and BMI-matched control group. The mechanisms
explaining this observation are unclear. Hypoxaemia is a likely
candidate since it is known to suppress the expression of
endothelial NO synthase,33 and previous studies have shown
that NOx is inversely related to nocturnal desaturation8 9 and
oxygen administration increases serum NOx in OSAS.9 On the
other hand, previous studies have shown that effective CPAP
therapy increases NO levels in OSAS.7 32 Furthermore, Lavie et al32
reported a significant decrease in circulating NO levels after CPAP
withdrawal for just one night. Our study confirms these previous
results using a highly robust design (randomised, placebo
controlled, crossover trial). Thus, our results showed that
treatment with CPAP for 3 months led to a significant
improvement in NO metabolites compared with placebo.
Strengths and potential limitations
As discussed above, the main strengths of the study are the
experimental design (randomised, placebo controlled, crossover
trial) and the careful selection of patients and controls (in whom
co-morbidities were carefully excluded). Yet, as in any study,
there are some potential limitations that deserve comment. First,
the sample size was relatively small. This was due to the
difficulty of including only middle-aged patients with newly
diagnosed OSAS who had no other diseases and were taking no
cardiovascular medication. Second, because our study included
only men, our results may not be directly applicable to women.
CONCLUSIONS
The results of this study show that OSAS causes oxidative
stress and reduces NOx bioavailability, and that CPAP therapy
normalises these biological abnormalities.
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ANSWER
From the question on page 580
The MRI shows cor triatriatum (fig 1). This is a rare congenital
abnormality accounting for 0.1% of all congenital cardiac
malformations.1 It is caused by a failure of common pulmonary
vein resorption during cardiogenesis. This leads to persistence of
a diaphragm-like membrane dividing the left atrium.
Communication between the chambers is via one or more
orifices. The size of this communication determines the degree
of obstruction to pulmonary venous return. Elevation in
pulmonary venous pressure and pulmonary vascular resistance
may cause pulmonary hypertension (PHT).2 As in this case,
echocardiography may not reveal the left atrial membrane.
Normal pregnancy is characterised by a 45–50% increase in
blood volume and cardiac output and a reduction in vascular
resistance.3 In pulmonary arterial hypertension (PAH), which is
an important cause of PHT, the stiff pulmonary circulation
cannot accommodate the increased blood flow, which may
cause the right ventricle to fail. A dilated right ventricle can, in
turn, reduce left heart filling and hence lead to low cardiac
output heart failure.4
Published case reports of PHT in pregnancy reveal that the
maternal mortality rate is between 30% and 56% depending on
the aetiology, although the true mortality may be higher. Fetal/
neonatal mortality is 10–12%. Most women die in the
postpartum period of treatment-resistant right heart failure.5
It is vital to establish the aetiology of PHT and not assume
that all causes are related to PAH. In cases such as these, specific
PAH therapies are unhelpful and may even be contraindicated.
Cardiac MRI may be particularly useful in pregnancy as it
does not expose the mother or fetus to radiation and can help
determine the aetiology and severity of the haemodynamic
changes.6
Our patient had a forceps delivery under combined spinal/
epidural anaesthesia at 36 weeks gestation. She did not require
any specific therapy for her PHT during pregnancy or
postpartum. She has declined de-roofing surgery to correct the
cor triatriatum. Mother and baby are doing well.
Thorax 2009;64:586. doi:10.1136/thx.2008.105353a
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Figure 1 MRI showing cor triatriatum. AC, antechamber; LA, left
atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.
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